[go: up one dir, main page]

MX2021014540A - Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama. - Google Patents

Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.

Info

Publication number
MX2021014540A
MX2021014540A MX2021014540A MX2021014540A MX2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A
Authority
MX
Mexico
Prior art keywords
compositions
methods
breast cancer
same
leuprolide acetate
Prior art date
Application number
MX2021014540A
Other languages
English (en)
Inventor
John Middleton
Avinash Nangia
John Arthur Mclane
Terri L Morton
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of MX2021014540A publication Critical patent/MX2021014540A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Composiciones y métodos para suprimir la función ovárica en sujetos con cáncer de mama de receptor de hormona-positivo.
MX2021014540A 2019-05-27 2020-05-26 Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama. MX2021014540A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (1)

Publication Number Publication Date
MX2021014540A true MX2021014540A (es) 2022-04-12

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014540A MX2021014540A (es) 2019-05-27 2020-05-26 Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.

Country Status (17)

Country Link
US (2) US12453754B2 (es)
EP (1) EP3975990A1 (es)
JP (1) JP7664855B2 (es)
KR (1) KR20220041782A (es)
CN (1) CN114144169A (es)
AR (1) AR119021A1 (es)
AU (1) AU2020284587B2 (es)
BR (1) BR112021023904A2 (es)
CA (1) CA3141456A1 (es)
EA (1) EA202193257A1 (es)
IL (1) IL288503A (es)
MX (1) MX2021014540A (es)
PH (1) PH12021552976A1 (es)
SG (1) SG11202112888RA (es)
TW (1) TWI757753B (es)
UY (1) UY38717A (es)
WO (1) WO2020240417A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014540A (es) 2019-05-27 2022-04-12 Tolmar International Ltd Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.
SI4135830T1 (sl) 2020-12-23 2025-03-31 Tolmar International Limited Sistemi in metode za mešanje sklopov ventilov brizge
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
KR101728868B1 (ko) 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
PT3660073T (pt) * 2007-02-15 2023-08-31 Tolmar International Ltd Poli-(lactídeo-co-glicolídeo) de libertação imediata reduzida
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
ES3023516T3 (en) * 2011-10-14 2025-06-02 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
MX2021014540A (es) 2019-05-27 2022-04-12 Tolmar International Ltd Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
SI4135830T1 (sl) 2020-12-23 2025-03-31 Tolmar International Limited Sistemi in metode za mešanje sklopov ventilov brizge
JP2024530136A (ja) 2021-08-19 2024-08-16 ケアフュージョン ３０３、インコーポレイテッド 直接採血用の流出防止コンポーネントを備えたｐｉｖｃ一体型溶血低減アクセサリ
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Also Published As

Publication number Publication date
TWI757753B (zh) 2022-03-11
JP2022535694A (ja) 2022-08-10
AU2020284587B2 (en) 2025-09-18
EP3975990A1 (en) 2022-04-06
PH12021552976A1 (en) 2022-07-04
US20260027176A1 (en) 2026-01-29
SG11202112888RA (en) 2021-12-30
KR20220041782A (ko) 2022-04-01
AU2020284587A1 (en) 2022-01-06
WO2020240417A1 (en) 2020-12-03
US20220265760A1 (en) 2022-08-25
IL288503A (en) 2022-01-01
US12453754B2 (en) 2025-10-28
JP7664855B2 (ja) 2025-04-18
EA202193257A1 (ru) 2022-03-10
CA3141456A1 (en) 2020-12-03
AR119021A1 (es) 2021-11-17
BR112021023904A2 (pt) 2022-02-01
CN114144169A (zh) 2022-03-04
UY38717A (es) 2020-11-30
TW202110472A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
MX2021014540A (es) Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
MX2021014286A (es) Proteinas multiespecificas.
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
MX2022002682A (es) Anticuerpos anti-cd73.
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
NI201700012A (es) Inhibidores de la proteina quinasa c y métodos de su uso
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
MX2019010440A (es) Proteinas de union a antigeno anti-tigit y metodos de uso de las mismas.
MX2022006132A (es) Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
PL423259A1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
CL2020002340A1 (es) Anti–cd25 para el agotamiento de células específicas de tumores
MX2021014729A (es) Metodos y composiciones para tratar enfermedades autoinmunitarias.
HK1248256A1 (zh) L型电压门控通道抗体及其相关方法